tbuckley/cabot-search huggingface dataset:
Diabetes Nutrition and Complications Trial (DNCT): Food Intake and Targets of Diabetes Treatment in a Sample of Spanish People With Diabetes
Journal: Diabetes Care (1997)

OBJECTIVE To know the nutritional pattern of people with diabetes in Spain and that pattern's relationship with targets of metabolic control. RESEARCH DESIGN AND METHODS The Diabetes Nutrition and Complications Trial (DNCT) is a prospective multicenter study designed to determine the nutritional behavior of diabetic patients in Spain using 7-day food diaries. A total of 337 diabetic patients, 144 (70 men and 74 women) with type I and 193 (81 men and 112 women) with type II diabetes, satisfactorily completed the 7-day food diaries from May 1993 to December 1994. RESULTS The median energy intake of the Spanish diabetic subjects was between 1,453 and 2,217 kcal/day (6.1–9.3 MJ/day), distributed as follows: 38–40% from carbohydrate, 19–23% from protein, and 36–41.5% from fat (11.1–13.9% saturated fatty acids, 4.6–5.8% polyunsaturated fatty acids, and 19.7–21.9% monounsaturated fatty acids). Of the subjects, 69% had a cholesterol level &amp;lt;5.6 mmol, 97% had an HDL cholesterol level &amp;gt;0.9 mmol, and 85% had a triglyceride level &amp;lt;1.7 mmol, while &amp;lt;36% had an HbA1c value &amp;gt;8%. CONCLUSIONS People with diabetes in Spain have near-optimal serum lipid levels and maintain reasonably good blood glucose control and BMI, suggesting that diabetes management that includes the usual Spanish diet, which is low in carbohydrates and high in fat, especially monounsaturated fat, might be adequate.
Omalizumab rapidly improves angioedema‐related quality of life in adult patients with chronic spontaneous urticaria: X‐<scp>ACT</scp> study data
Authors: P. Staubach, M. Metz, N. Chapman‐Rothe, C. Sieder, M. Bräutigam, M. Maurer, K. Weller
Journal: Allergy (2017)

Abstract Background The X‐ ACT study aimed to examine the effect of omalizumab treatment on quality of life (QoL) in chronic spontaneous urticaria ( CSU ) patients with angioedema refractory to high doses of H 1 ‐antihistamines. Methods In X‐ ACT , a phase III , double‐blind, placebo‐controlled study, CSU patients (18‐75 years) with ≥4 angioedema episodes during the 6 months before inclusion were randomized (1:1) to receive omalizumab 300 mg or placebo every 4 weeks for 28 weeks. Angioedema‐related QoL, skin‐related QoL impairment, and psychological well‐being were assessed. Results Ninety‐one patients were randomized and 68 (omalizumab, n = 35; placebo, n = 33) completed the 28‐week treatment period. At baseline, the mean ( SD ) total Angioedema QoL ( AE ‐QoL; 56.2 [18.7] and 59.9 [19.2]) and Dermatology Life Quality Index ( DLQI ; 14.6 [5.7] and 16.6 [7.3]) score were high in the omalizumab and placebo group, respectively. At Week 4 (after the first treatment), the least squares mean difference in the AE ‐QoL and DLQI score between groups was −17.6 ( P &lt; .001) and −7.2 ( P &lt; .001), respectively. Significant QoL improvements in the omalizumab vs placebo groups continued until Week 28, but returned to placebo levels at the follow‐up visit. The mean ( SD ) baseline 5‐item World Health Organization Well‐being Index was 10.0 (5.5, omalizumab) and 7.7 (5.3, placebo), which increased above the depression threshold (&lt;13) from Week 4 and throughout with omalizumab but not placebo treatment. Compared to placebo, omalizumab was also associated with decreased fear of suffocation due to angioedema. Conclusions Our findings support omalizumab treatment in patients with severe H1‐antihistamine‐refractory CSU with angioedema.
Loss of mTORC1 signaling alters pancreatic α cell mass and impairs glucagon secretion
Authors: Nadejda Bozadjieva, Manuel Blandino-Rosano, Jennifer Chase, Xiao-Qing Dai, Kelsey Cummings, Jennifer Gimeno, Danielle Dean, Alvin C. Powers, George K. Gittes, Markus A. Rüegg, Michael N. Hall, Patrick E. MacDonald, Ernesto Bernal-Mizrachi
Journal: Journal of Clinical Investigation (2017)

Glucagon plays a major role in the regulation of glucose homeostasis during fed and fasting states. However, the mechanisms responsible for the regulation of pancreatic α cell mass and function are not completely understood. In the current study, we identified mTOR complex 1 (mTORC1) as a major regulator of α cell mass and glucagon secretion. Using mice with tissue-specific deletion of the mTORC1 regulator Raptor in α cells (αRaptorKO), we showed that mTORC1 signaling is dispensable for α cell development, but essential for α cell maturation during the transition from a milk-based diet to a chow-based diet after weaning. Moreover, inhibition of mTORC1 signaling in αRaptorKO mice and in WT animals exposed to chronic rapamycin administration decreased glucagon content and glucagon secretion. In αRaptorKO mice, impaired glucagon secretion occurred in response to different secretagogues and was mediated by alterations in KATP channel subunit expression and activity. Additionally, our data identify the mTORC1/FoxA2 axis as a link between mTORC1 and transcriptional regulation of key genes responsible for α cell function. Thus, our results reveal a potential function of mTORC1 in nutrient-dependent regulation of glucagon secretion and identify a role for mTORC1 in controlling α cell–mass maintenance.
Dual-Task Gait And Incident Dementia—A Step Forward, But Not There Yet—Reply
Authors: Manuel Montero-Odasso, Richard Camicioli, Susan W Muir-Hunter
Journal: JAMA Neurology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
SmiNet-2 : descrição de um sistema de vigilância por Internet de doenças transmissiveis na Suecia
Authors: P Rolfhamre, A Janson, M Arneborn, K Ekdahl
Journal: Eurosurveillance (2006)

Os sistemas electronicos de vigilância de doencas transmissiveis melhoram a qualidade da vigilância, simplificando as declaracoes, aperfecionando a exhaustividade e acelerando o processo de notificacao. 
Neste artigo, descrevemos os principios e as technologias de SmiNet-2, o novo sistema regional e nacional de vigilância de doencas transmissiveis na Suecia. Com esse sistema, a notificacao pode ser feita pelos medicos (por meio de um formulario na rede) ou pelos laboratorios (diretamente pelo sistema de dados de laboratorios) usando Internet. Com um numero de identificacao pessoal unico, SmiNet-2 fusiona automaticamente as declaracoes clinicas e de laboratorio com os registros de casos. Os utilizadores autorisados, ao nivel nacional e regional, utilizem um servidor central comum que contem todas as declaracoes e registros de casos. Allem disso, SmiNet-2 tem servidores a nivel provincial, com instrumentos uteis para as investigacoes de surtos, a pesquisa de contatos e a gestao de casos. 
SmiNet-2 foi iniciado em Setembro de 2004. As provincias recebem ate 90% de todas as notificacoes electronicamente. Durante o primeiro ano, SmiNet-2 recebeu 54 980 notificacoes clinicas e 32 765 declaracoes de laboratorios que generarem 58 891 registros de casos. 
Dado que a maioria dos medicos na Suecia acedem facilmente a Internet, as notificacoes por Internet podem ser generalizadas. Neste contexto, SmiNet-2, comparado com outros sistemas, apresenta certas avantagens importantes : a rapidez no fluxo de dados (incluindo o nivel nacional), a integracao de declaracoes clinicas e de laboratorios, e a capacidade de tratar mais de 50 doencas com formularios de notificacao a medida num sistema unico.
Survey on dose reductions in R-CHOP therapy for DLBCL -Questionnaire results from members of the JSMO by the JASCC-
Authors: Isao Yoshida, Shun-ichi Kimura, Minoru Yoshida, Hiroyuki Fujita, Hiromichi Iwasaki, Shingo Yano, Hitoshi Kusaba, Kosuke Takahashi, Takuho Okamura, Norio Ohmagari, Kazuo Tamura
Journal: Annals of Oncology (2017)
PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock
Authors: Holger Thiele, Ibrahim Akin, Marcus Sandri, Georg Fuernau, Suzanne de Waha, Roza Meyer-Saraei, Peter Nordbeck, Tobias Geisler, Ulf Landmesser, Carsten Skurk, Andreas Fach, Harald Lapp, Jan J. Piek, Marko Noc, Tomaž Goslar, Stephan B. Felix, Lars S. Maier, Janina Stepinska, Keith Oldroyd, Pranas Serpytis, Gilles Montalescot, Olivier Barthelemy, Kurt Huber, Stephan Windecker, Stefano Savonitto, Patrizia Torremante, Christiaan Vrints, Steffen Schneider, Steffen Desch, Uwe Zeymer
Journal: New England Journal of Medicine (2017)

In patients who have acute myocardial infarction with cardiogenic shock, early revascularization of the culprit artery by means of percutaneous coronary intervention (PCI) improves outcomes. However, the majority of patients with cardiogenic shock have multivessel disease, and whether PCI should be performed immediately for stenoses in nonculprit arteries is controversial.In this multicenter trial, we randomly assigned 706 patients who had multivessel disease, acute myocardial infarction, and cardiogenic shock to one of two initial revascularization strategies: either PCI of the culprit lesion only, with the option of staged revascularization of nonculprit lesions, or immediate multivessel PCI. The primary end point was a composite of death or severe renal failure leading to renal-replacement therapy within 30 days after randomization. Safety end points included bleeding and stroke.At 30 days, the composite primary end point of death or renal-replacement therapy had occurred in 158 of the 344 patients (45.9%) in the culprit-lesion-only PCI group and in 189 of the 341 patients (55.4%) in the multivessel PCI group (relative risk, 0.83; 95% confidence interval [CI], 0.71 to 0.96; P=0.01). The relative risk of death in the culprit-lesion-only PCI group as compared with the multivessel PCI group was 0.84 (95% CI, 0.72 to 0.98; P=0.03), and the relative risk of renal-replacement therapy was 0.71 (95% CI, 0.49 to 1.03; P=0.07). The time to hemodynamic stabilization, the risk of catecholamine therapy and the duration of such therapy, the levels of troponin T and creatine kinase, and the rates of bleeding and stroke did not differ significantly between the two groups.Among patients who had multivessel coronary artery disease and acute myocardial infarction with cardiogenic shock, the 30-day risk of a composite of death or severe renal failure leading to renal-replacement therapy was lower among those who initially underwent PCI of the culprit lesion only than among those who underwent immediate multivessel PCI. (Funded by the European Union 7th Framework Program and others; CULPRIT-SHOCK ClinicalTrials.gov number, NCT01927549 .).
Safety and efficacy of chemoradiotherapy for high risk stage II laryngeal cancer
Authors: Satoshi Hamauchi, Tomoya Yokota, Yusuke Onozawa, Hirofumi Ogawa, Tsuyoshi Onoe, Tomoyuki Kamijo, Yoshiyuki Iida, Tetsuo Nishimura, Tetsuro Onitsuka, Hirofumi Yasui
Journal: Annals of Oncology (2017)
Abstract 17239: Ifn-γ Aggravated Neointimal Hyperplasia By Inducing Er Stress-mediated Apoptosis in Macrophages Through Accelerating Lxr-α Degradation
Authors: Qiang Zhao, Yan Zhang, Dong Zhou, Fuxue Deng, Lisha Zhang, Wangge Ma, Lizhe Sun, Yue Wu, Zuyi Yuan, Juan Zhou
Journal: Circulation (2016)

Introduction:  Neointimal hyperplasia is the major cause of restenosis after percutaneous coronary interventions, which is characterized by thicken arterial wall and decreased arterial lumen space. Both interferon-γ (IFN-γ) and macrophages play nonredundant roles in pathogenesis of vascular intimal hyperplasia. But until now, the underlying mechanisms remain elusive and need to be further addressed.   Methods and Results:  IFN-γ decreased the protein expression of liver X receptor (LXR)-α dose-dependently, but not LXR-β, in Raw264.7 and mouse peritoneal macrophages. IFN-γ did not influence the mRNA expression of LXR-α. IFN-γ increased polyubiquitin chain formation on LXR-α, resulting accelerated degradation of LXR-α in macrophages which could be prevented by MG-132, a proteasome inhibitor. Immunoprecipitation and Western blot analysis showed that LXR-α bound both with p-STAT1 and PIAS1 in macrophages under the action of IFN-γ. STAT1 inhibition by fludarabine or PIAS1 knockout by transfection of shRNA lentivirus not only reduced ubiquitination but also up-regulated the protein expression of LXR-α in macrophages treated by IFN-γ. Moreover, IFN-γ increased expression of p-PERK, p-eIF2α and CHOP, which could be partially reversed by LXR agonist T0901317. IFN-γ augmented apoptosis of macrophages, which was assessed by Annexin V and PI staining. Inhibition of ER stress by 4-phenylbutyric acid (4-PBA) and treatment with T0901317 alleviated apoptosis induced by IFN-γ in macrophages. The thickness of carotid intima increased obviously after ligation for 4 weeks in male ApoE -/-  mice and was suppressed notably by T0901317 and 4-PBA treatment. Meanwhile, T0901317 and 4-PBA treatment reduced expression of p-eIF2α and CHOP of CD68 +  macrophages and cellular apoptosis in hyperplastic neointimal tissue, which were evaluated by immunofluorescence and TUNEL staining, respectively.   Conclusions:  These results defined an unexpected role of IFN-γ and LXR-α in the development of neointimal hyperplasia. IFN-γ accelerated the degradation of LXR-α through STAT1/PIAS1 dependent way and promoted ER stress-mediated apoptosis in macrophages. Ameliorate restenosis and vascular remodeling after PCI by targeting LXR-α may be a promising new strategy.
TCT-741 Real world one-year clinical outcome of biodegradable polymer sirolimus-eluting stent in single center, all-comers, consecutive 1727 cases
Authors: Yutaka Tadano, Daitaro Kanno, Daisuke Hachinohe, Yoshifumi Kashima, Morio Enomoto, Ken Kobayashi, Umihiko Kaneko, Takuro Sugie, Tomohiko Watanabe, Tsutomu Fujita
Journal: Journal of the American College of Cardiology (2017)
Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial
Authors: Aneliya Parvanova, Matias Trillini, Manuel A Podestà, Ilian Petrov Iliev, Barbara Ruggiero, Manuela Abbate, Annalisa Perna, Francesco Peraro, Olimpia Diadei, Nadia Rubis, Flavio Gaspari, Fabiola Carrara, Nadia Stucchi, Antonio Belviso, Antonio C Bossi, Roberto Trevisan, Giuseppe Remuzzi, Martin de Borst, Piero Ruggenenti, Norberto Perico, Piero Ruggenenti, Giuseppe Remuzzi, Stefano Rota, Matias Trillini, Barbara Ruggiero, Maria Carolina Aparicio, Silvia Prandini, Daniela Cugini, Giulia Gherardi, Manuel A Podestà, Roberto Trevisan, Anna Corsi, Antonio C. Bossi, Aneliya Parvanova, Ilian Petrov Iliev, S Yakymchuk, Veruscka Lecchi, Antonio Belviso, Ruggero Mangili, Nadia Rubis, Wally Calini, Olimpia Diadei, Bogdan Ene-Iordache, Sergio Carminati, Davide Martinetti, Giovanni Antonio Giuliano, Annalisa Perna, Francesco Peraro, Angela Russo, Flavio Gaspari, Fabiola Carrara, Silvia Ferrari, Nadia Stucchi, Antonio Nicola Cannata, Paola Boccardo, Sara Peracchi, Martin De Borst, Serena Bettoni, Irene Cattaneo, Davide Franchina, Haian Ha Phan, Grace Igiraneza, Tamas Kaucsár, Sergio Luis Lima, Meg Lunney, Huong Tran
Journal: The Lancet Diabetes & Endocrinology (2017)
TCTAP A-159 Predictors of Acute Kidney Injury in Patients Undergoing Transcatheter Aortic Valve Replacement
Authors: Sang Yong Om, Yong-Hoon Yoon, Minsoo Kim, Hanbit Park, Sang-Cheol Cho, Sangwoo Park, Tae-Oh Kim, Sun Hack Lee, Osung Kwon, Kyusup Lee, Do-Yoon Kang, Jung-Min Ahn, Duk-Woo Park, Soo-Jin Kang, Seung-Whan Lee, Young-Hak Kim, Cheol Whan Lee, Seong-Wook Park, Seung-Jung Park
Journal: Journal of the American College of Cardiology (2018)
TCT-37 Sudden Cardiac Death in Patients with Severe Aortic Stenosis
Authors: Tomohiko Taniguchi, Takeshi Morimoto, Hiroki Shiomi, Kenji Ando, Takeshi Kitai, Yuichi Kawase, Chisato Izumi, Takeshi Kimura
Journal: Journal of the American College of Cardiology (2017)
Abstract 13548: Full Prescription Coverage versus Usual Prescription Coverage after Coronary Artery Bypass Graft Surgery for Recent Myocardial Infarction: Analysis from the MI FREEE Randomized Trial
Authors: Alexander Kulik, Nihar R Desai, William H Shrank, Elliott M Antman, Jerry Avorn, Robert J Glynn, Raisa Levin, Niteesh K Choudhry
Journal: Circulation (2012)

Background:  Patients recovering from coronary artery bypass graft surgery (CABG) have poor adherence to postoperative medical therapy. Eliminating out-of-pocket costs increases medication adherence after myocardial infarction (MI). We sought to evaluate the relative effectiveness of full prescription coverage versus usual formulary coverage for patients treated with or without CABG after recent MI.    Methods:  The MI FREEE (Free Rx Event and Economic Evaluation) Trial randomly assigned 5855 MI patients to full prescription coverage or usual prescription coverage for all statins, beta-blockers, angiotensin-converting-enzyme inhibitors (ACE), or angiotensin-receptor blockers (ARB). We assessed the impact of full prescription coverage on the cost, adherence, and clinical outcomes among the 1052 CABG and 4803 non-CABG patients using adjusted Cox proportion models and generalized estimating equations.    Results:  CABG patients were significantly older and had a greater incidence of co-morbid illness (P   Conclusion:  As compared with usual prescription coverage,providing full prescription drug coverage after CABG significantly increased adherence to secondary preventative therapy, reduced patient out-of-pocket costs, and was associated with a trend towards improved clinical outcomes.
Stem cell marker G-protein-coupled receptor GPR49/LGR5 is upregulated in basal cell carcinoma and promotes cell proliferation and tumor formation
Authors: Keiji Tanese, Mariko Fukuma, Taketo Yamada, Taisuke Mori, Akira Ishiko, Masayuki Amagai, Takeji Nishikawa, Michiie Sakamoto
Journal: Cancer Research (2008)

5420  The significance of Hedgehog (HH) signaling has been established in the development of basal cell carcinoma (BCC) and some visceral cancers, and several target genes of HH signaling have been described. However, their precise role in tumorigenesis and cell proliferation is not known. To identify genes responsible for tumor formation in BCC, we screened a DNA microarray database in human BCC cases, and orphan G-protein-coupled receptor GPR49/LGR5 was found to be upregulated in all cases. GPR49 is a novel gene reported as a marker in follicular stem cell and some other tissue stem cells. By real-time quantitative RT-PCR analysis, significant expression of GPR49 mRNA was observed in 19 of 20 cases (95%) compared to normal skin. On the other hand, other types of malignant epidermal tumors did not show significant upregulation of GPR49. Upregulation of GPR49 in BCC was confirmed by in situ hybridization in various histological subtypes. These results suggest that the expression of GPR49 is a specific feature of BCC among the various types of malignant epidermal tumors. Moreover, knocking down of mouse Gpr49 showed suppression of cell proliferation in mouse BCC cell line and overexpression of GPR49 in human immortalized keratinocyte HaCaT cells induced to proliferate. Furthermore, HaCaT cells overexpressing GPR49 showed tumor formation when transplanted to immunodeficient mice. In the histological examination, tumors made from GPR49 expressed HaCaT cells displayed mitotic figure with a high tendency towards proliferation and interstitial invasion. In addition, inhibition of the HH signaling pathway in a mouse BCC cell line downregulated endogenous Gpr49 and activation of HH signaling in mouse NIH3T3 cells upregulated endogenous GPR49. From these findings, we speculate that GPR49 is expressed under the control of HH signaling and promotes cell proliferation and tumor formation. Also, expression of GPR49 supports the close relationship between BCC and follicular stem cells.
Phytohemagglutinin chemosensitizes lung cancer cells to Liposomal Cisplatin by cell cycle arrest
Authors: Alexandre Tavartkiladze, Gaiane Simonia, Irine Andronikashvili, Rusudan Khutsishvili, Inga Shoshiashvili, Givi Tavartkiladze
Journal: Annals of Oncology (2017)
Nuevo brote de triquinosis en la región Midi-Pyrénées de Francia, septiembre - octubre de 1998
Authors: C Hemery, S Haeghebaert
Journal: Eurosurveillance (1999)

El 6 de octubre de 1998, se declararon once casos de triquinosis en los departamentos de Haute-Garonne y Tarn, Francia, al Departamento Regional de Salud Publica de la region Midi-Pyrenees (1). Todos los casos habian ingerido carne de caballo, adquirida en una carniceria de Toulouse y en otra de Castres. Se realizo una investigacion epidemiologica, veterinaria y parasitologica para evaluar la importancia del brote e identificar el vehiculo y la fuente de infeccion.
Comparison between four PD-L1 IHC assays and association with efficacy of Nivolumab in previously treated NSCLC patients
Authors: Yuki Sato, Daichi Fujimoto, Keiichiro Uehara, Yuki Imaoka, Kentaro Hayashi, Kaori Ishida, Junya Fukuoka, Yukihiro Imai, Keisuke Tomii
Journal: Annals of Oncology (2017)
Peri-operative management of overweight and obese children and adolescents
Authors: Corinne Lejus, Gilles Orliaguet, Frederique Servin, Christophe Dadure, Fabrice Michel, Christopher Brasher, Souhayl Dahmani
Journal: The Lancet Child & Adolescent Health (2017)

Obesity has become endemic, even in children. Systemic complications associated with obesity include metabolic syndrome, cardiovascular disease, and respiratory compromise. These comorbidities require adequate investigation, targeted optimisation, and, if surgery is required, specific management during the peri-operative period. Specific peri-operative strategies should be used for paediatric patients who are overweight or obese to prevent postoperative complications, and optimising the respiratory function during surgery is particularly crucial. This Review aims to provide up-to-date information on peri-operative management for physicians who are caring for children and adolescents (usually younger than 18 years) who are overweight or obese undergoing surgery, including bariatric surgery. We have particularly focussed on the physiological consequences of obesity-namely, obstructive sleep apnoea, respiratory compromise, and pharmacological considerations.